KCR Accomplishes ISO 9001:2008 Certification for All Company Services

26-May-2015 - Germany

KCR, a contract research Organization (CRO), has recently validated the quality and accuracy of its operations receiving ISO 9001:2008 Certification for all its services. The company achieved its first ISO 9001:2008 certification in February 2007, and was recertified in 2010 and 2013. This year KCR was certified again, including a number of newly added services required for the Full Service Trial Execution delivery.

“At KCR we are strongly focused on quality and compliance to assure that every clinical trial, as well as all our services are conducted according to the highest standards,” said Mike Jagielski, President & CEO of KCR. “The ISO 9001 Certificate accomplishment not only assures transparency of processes but also demonstrates a sound quality management system. These values are of great importance to our clients.”

Other news from the department politics & laws

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

PRAC recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors

DNA Microarrays Will Remain Important Tools Despite Competition from Other Technologies, According to a Healthtech Institute - Protein Arrays-Hope or Hype?

ThromboGenics Announces that Microplasmin Meets Primary Endpoint in Phase III Trial for Vitreomacular Adhesion - Highly significant trial result (p=0.003) demonstrates the potential of microplasmin in the treatment of retinal disease

CEL-SCI reports on adjuvant properties of CEL-1000 peptide to enhance vaccines - Zimmerman: "CEL-1000 does not appear to induce self- directed or cross-reactive antibodies, can be well characterized and is inexpensive to manufacture."

Multiplicom receives €200,000 grant for novel non-invasive pre-natal test - IWT grant to support development of early aneuploidy detection during pregnancy

Asahi Kasei acquires German biotech specialist for €780 million - The Japanese corporation to acquire Aicuris to accelerate growth in severe infectious diseases

Asahi Kasei acquires German biotech specialist for €780 million - The Japanese corporation to acquire Aicuris to accelerate growth in severe infectious diseases

Scientists see how a protein preserves vision in a unique group of diabetic patients

Immune cells can switch from ‘gang members’ to ‘police officers’

Innovative Biosensors and Massachusetts Institute of Technology Announce Licensing Agreement for Biosensor Technology

Zealand Pharma and PolyTherics enter Collaboration Agreement for novel optimised biopharmaceuticals

Mucosis B.V. and PATH Sign Agreement to Pursue Mimopath-Based Oral Diarrhea Vaccines

Gastrotech signs licensing agreement with Eli Lilly following positive clinical data on compound for Irritable Bowel Syndrome